Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845226 | 0.87 | NPC1 (0.35) | RAB9ANPC1SMN1; SMN2MGLLKMT2A | |
| SCHEMBL29760265 | 0.84 | NPC1 (0.38) | RAB9ANPC1SMN1; SMN2MGLLKMT2A | |
| SCHEMBL21462908 | 0.84 | NPC1 (0.38) | RAB9ANPC1SMN1; SMN2MGLLKMT2A | |
| SCHEMBL23163078 | 0.84 | NPC1 (0.38) | RAB9ANPC1SMN1; SMN2MGLLKMT2A | |
| SCHEMBL30730269 | 0.79 | KDM4E (0.35) | RAB9ANPC1SMN1; SMN2MGLLKDM4E | |
| SCHEMBL21471127 | 0.77 | NPC1 (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL20350237 | 0.77 | NPC1 (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL21471128 | 0.77 | NPC1 (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL26683935 | 0.76 | CYP19A1 (0.43) | RAB9AKMT2AKDM4ECCR5 | |
| SCHEMBL26683940 | 0.76 | CYP19A1 (0.43) | RAB9AKMT2AKDM4ECCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041729-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-4041729-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021070054-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, SAMHD1, POLR2H | RAB9A 1878/4885NPC1 376/4885SMN1; SMN2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.